These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36933395)

  • 21. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.
    Agarwal S; Sasane S; Deshmukh P; Rami B; Bandyopadhyay D; Giri P; Giri S; Jain M; Desai RC
    ACS Med Chem Lett; 2016 Dec; 7(12):1134-1138. PubMed ID: 27994752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.
    Mancini AD; Bertrand G; Vivot K; Carpentier É; Tremblay C; Ghislain J; Bouvier M; Poitout V
    J Biol Chem; 2015 Aug; 290(34):21131-21140. PubMed ID: 26157145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
    Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
    Zhang X; Macielag MJ
    Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists.
    Zhao X; Yoon DO; Yoo J; Park HJ
    J Med Chem; 2021 Apr; 64(7):4130-4149. PubMed ID: 33769827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
    Mancini AD; Poitout V
    Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
    Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
    Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.
    Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S
    Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
    Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).
    Rodrigues DA; Pinheiro PSM; Ferreira TTDSC; Thota S; Fraga CAM
    Chem Biol Drug Des; 2018 Mar; 91(3):668-680. PubMed ID: 29068547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulating GPR40: therapeutic promise and potential in diabetes.
    Poitout V; Lin DC
    Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.